Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biomea Fusion Inc.
Headquarters: Redwood City, CA, United States of America
Website: https://biomeafusion.com/
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Tom Butler, MBA
Number Of Employees: 103
Enterprise Value: $328,662,522
PE Ratio: -0.66
Exchange/Ticker 1: NASDAQ:BMEA
Exchange/Ticker 2: N/A
Latest Market Cap: $96,394,896
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
BioCentury | Aug 31, 2023
Management Tracks
Oxford Science Enterprises names new CEO, first CIO
Plus: Frías hired as CMO at Biomea Fusion, and updates from Astraveus and Septerna
BioCentury | Jun 27, 2023
Product Development
June 26 Quick Takes: Fibrogen sinks on IPF discontinuation
Plus: Vertex’s diabetes cell therapy leads to insulin independence; Agios heads to Phase III in sickle cell; and updates from Biomea, Shionogi, Sagimet and more
BioCentury | Mar 28, 2023
Product Development
Biomea shares double on Phase II data for new diabetes mechanism
The company believes its covalent Menin degrader is increasing the pool of β islet cells, without risk of hypoglycemia
BioCentury | Feb 2, 2022
Management Tracks
Roche’s William Pao joins Pfizer as CDO
Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
BioCentury | Nov 24, 2021
Product Development
Patient death, FDA hold slow Kura’s timeline for menin inhibitor
Kura believes overall risk of differentiation syndrome is manageable, hopes to resolve partial clinical hold quickly
BioCentury | Apr 17, 2021
Finance
Biotech IPOs continue attracting cash
IPOs by Recursion, Biomea and Akoya continue the trend of strong debuts by biotech companies on NASDAQ
BioCentury | Mar 28, 2021
Finance
Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO
Menin inhibitor moving toward clinic three months after series A
Items per page:
1 - 8 of 8